This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -10.00% and -6.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review
by Zacks Equity Research
The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
by Zacks Equity Research
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
by Zacks Equity Research
Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -10.34% and -17.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.
Stock Market News for Feb 26, 2021
by Zacks Equity Research
U.S. stock markets closed sharply lower on Thursday as rising bond yields raised concerns among market participants on risky assets like equities
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -61.11% and -31.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
by Zacks Equity Research
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.
Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5%
by Zacks Equity Research
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.
CRISPR Gene Editing: Owning the Future of Medicine
by Kevin Cook
In the Century of Biology, it pays to own the future of curing disease at the root.
Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 95.83% and 101.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Stocks: Buy or Trade?
by Kevin Cook
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
BioMarin Down on CRL From FDA for Hemophilia A Candidate
by Zacks Equity Research
BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -163.41% and -71.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?